Pfizer: new Emblaveo antibiotic approved in the EU

(CercleFinance.com) - Pfizer announced on Monday that the European Commission has approved the marketing of Emblaveo, its new antibiotic for the treatment of the most resistant infections.


This antibiotic targets complex intra-abdominal infections, nosocomial pneumonia such as ventilator-associated pneumonia, and urinary tract infections such as pyelonephritis.

It has also been approved for the treatment of Gram-negative bacterial infections, an area where treatment options have hitherto been limited due to multi-drug resistance.

Emblaveo - which was jointly developed with AbbVie - is to be marketed internationally by Pfizer, with AbbVie holding distribution rights in the USA and Canada.

Copyright (c) 2024 CercleFinance.com. All rights reserved.